Comparing treatments to stop bleeding in patients: A clinical study of local bleeding control methods

ISRCTN ISRCTN19155058
DOI https://doi.org/10.1186/ISRCTN19155058
Secondary identifying numbers 5033
Submission date
23/05/2025
Registration date
29/05/2025
Last edited
29/05/2025
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Oral Health
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Some people take medications like aspirin or warfarin to prevent blood clots, but these medicines can make it harder to stop bleeding after a tooth is removed. This study looked at two special dressings—Surgicel and Gelfoam—that help stop bleeding. The goal was to see which one works better at controlling bleeding and helping the gums heal after tooth extraction in people taking these medications.

Who can participate?
Adults aged 40 to 75 years who are taking a daily dose of aspirin (80 mg) or warfarin can take part. People on warfarin must have stable blood test results (INR between 2 and 3.5). Participants must need simple tooth extractions (not complex surgery) and agree not to change their medication during the study.

What does the study involve?
Each participant had two similar teeth removed—one on each side of the mouth. One side was treated with Gelfoam and the other with Surgicel to stop the bleeding. Researchers then checked how much bleeding occurred, how well the gums healed, and how much pain the person felt. These checks were done on day 3 and day 7 after the extraction, and bleeding was also checked 24 hours after the procedure.

What are the possible benefits and risks of participating?
Participants may benefit from close monitoring and care after their tooth extractions. The study could also help improve treatment for others in the future. Risks are similar to those of a normal tooth extraction, such as bleeding, pain, or infection, but all participants were carefully monitored.

Where is the study run from?
University of Damascus (Syria)

When is the study starting and how long is it expected to run for?
November 2022 to December 2024.

Who is funding the study?
University of Damascus (Syria)

Who is the main contact?
Walaa Ali AL-Suliman, Walaa2.alsuliman2@damascusuniversity.edu.sy

Contact information

Mrs Walaa ALSULIMAN
Public, Principal Investigator

Damascus University
Damascus
-
Syria

ORCiD logoORCID ID 0009-0004-8612-043X
Email Walaaalsuliman2@gmail.com
Dr Salim al-hafyan
Scientific

Damascus University
Damascus
-
Syria

ORCiD logoORCID ID 0000-0001-8653-588X
Email saleembio89@gmail.com
Prof Issa Wehbeh
Scientific

Department of Oral and Maxillofacial Surgery
Faculty of Dentistry, Damascus University
Damascus
-
Syria

Email issa58.wehbeh@damascusuniversity.edu.sy

Study information

Study designComparative clinical study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Dental clinic, Hospital, Laboratory, University/medical school/dental school
Study typeTreatment, Efficacy
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titleComparative study of local haemostatic agent on hemorrhagic patients (clinical study)
Study objectivesThis study aims to evaluate and compare the effectiveness of Gelfoam and Sergocel in controlling bleeding in patients taking aspirin and warfarin, to ensure safe and effective solutions for bleeding control during dental extraction procedures. The study also seeks to fill the knowledge gap in the use of hemostatic agents in patients with blood clotting disorders by providing clinical data that can contribute to improving therapeutic practices and selecting the optimal dressing for each case, thus enhancing the quality of care provided to patients at risk of bleeding.
Ethics approval(s)

Approved 16/11/2022, The Institutional Biomedical Research Ethics Committee (Damascus University, Damascus, -, Syria; -; vice.research@damascusuniversity.edu.sy), ref: DN-150525-H27

Health condition(s) or problem(s) studiedPreventing the risk of bleeding in patients taking the anticoagulants aspirin and warfarin
InterventionA clinical study was conducted on 40 patients, divided into two groups based on the type of anticoagulant used (aspirin or warfarin). Each patient received treatment with different hemostatic dressings: Gelfoam was applied to one side and Surgicel to the other. Bleeding was assessed using the VIBe scale, and the rate of gingival healing was measured using the Gingival Healing Index (GHI) on days three (D3) and seven (D7). Pain was also assessed using the Visual Analogue Scale (VAS), and late bleeding rates were analyzed 24 hours after extraction.
Intervention typeProcedure/Surgery
Primary outcome measure1. Bleeding severity is measured using the VIBe scale at baseline, day 3, and day 7
2. Gingival healing is measured using the Gingival Healing Index (GHI) at day 3 and day 7
3. Pain intensity is measured using the Visual Analogue Scale (VAS) at baseline, day 3, and day 7
4. Late bleeding occurrence is measured using clinical observation at 24 hours after extraction
Secondary outcome measuresThere are no secondary outcome measures
Overall study start date16/11/2022
Completion date22/12/2024

Eligibility

Participant type(s)Population
Age groupSenior
Lower age limit40 Years
Upper age limit75 Years
SexBoth
Target number of participants45
Total final enrolment40
Key inclusion criteria1. Age between 40 and 75 years.
2. Patients use aspirin at a daily dose of 80 mg or oral warfarin.
3. Patients using warfarin must have a stable INR value within the therapeutic range (2-3.5) [23].
4. Obtaining written informed consent from all participants, with their commitment to maintaining the anticoagulant doses unchanged throughout the study period.
5. Requirement for simple tooth extractions of paired teeth, without the need for complex surgical intervention.
Key exclusion criteria1. Presence of uncontrolled systemic diseases that contraindicate tooth extraction.
2. Participation in other clinical trials during the study period is necessary to avoid treatment overlap and influence on results.
3. Unstable INR, where patients with fluctuations in INR outside the required therapeutic range (2-3.5) before extraction or during follow-up were excluded.
4. Severe alcohol or tobacco dependence due to their negative effects on wound healing post-extraction
Date of first enrolment16/11/2022
Date of final enrolment16/12/2023

Locations

Countries of recruitment

  • India
  • Iran
  • Iraq
  • Jordan
  • Kuwait
  • Lebanon
  • Morocco
  • Syria

Study participating centres

Damascus University
Faculty of Dentistry
Mezzeh district
Damascus
-
Syria
Al-Mowasat University Hospital
Department of Oral and Maxillofacial Surgery
Damascus
-
Syria

Sponsor information

Damascus University
Government

Funders

Funder type

University/education

Damascus University
Government organisation / Universities (academic only)
Alternative name(s)
University of Damascus, جَامِعَةُ دِمَشْقَ, DU
Location
Syria

Results and Publications

Intention to publish date22/11/2025
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planCurrently in the research publication stage in the journal BMC Oral Health.
IPD sharing planThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request:
Walaa2.alsuliman2@damascusuniversity.edu.sy
issa58.wehbeh@damascusuniversity.edu.sy
salim.alhafyan@aust.edu.sy
saleembio89@gmail.com

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Other unpublished results 28/05/2025 No No
Statistical Analysis Plan 28/05/2025 No No

Additional files

47394 results summary.pdf
47394 statistical analysis plan.pdf

Editorial Notes

29/05/2025: Trial's existence confirmed by Damascus University Ethics Committee.